Valens Cannabis Company Raises $46M Via Bought Deal Offering Of Units
The Valens Company Inc. (TSX: VLNS) (OTCQX: VLNCF) has secured some $46 million in financing through a bought deal public offering of its units.
40 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
BriaCell Therapeutics Corp. (NASDAQ: BCTX) shares jumped 147.3% to $7.86 after the company provided an update on the overall survival (OS) data on its previously disclosed heavily pretreated advanced breast cancer patients.
Super Micro Computer Targets 2M Global Servers Annually at Lower Cost By Summer 2021
Super Micro Computer Inc (NASDAQ:SMCI) doubled its manufacturing capacity to meet the global Cloud, AI, and 5G/Edge induced server and storage…
Why Shares Of Urban One Are Trading Higher Today
Urban One (NASDAQ: UONE) shares are trading higher amid investor anticipation of Juneteenth, during which the stock saw a run up last year.
Mereo’s Alvelestat Shows Encouraging Biomarker Data In Bronchiolitis Obliterans Syndrome
Mereo BioPharma Group plc (NASDAQ:MREO) has announced data from an interim analysis of an investigator-initiated study of alvelestat, in patients with…
Why Constellation Pharmaceuticals Is Soaring Today
Constellation Pharmaceuticals Inc (NASDAQ: CNST) is trading higher Wednesday morning after an announcement that MorphoSys AG (NASDAQ: MOR) will acquire the company.
Is Vertex Energy’s Stock Stock About To Hit Resistance?
Markets have memories.
This means a particular level could be important for a long time. The importance may last for weeks, months, or even years.
This is why shares of Vertex Energy, Inc. (NASDAQ: VTNR) may soon hit resistance.
Seres Therapeutics Gets FDA Green Signal to Start SER-155 Human Trials
The FDA has signed off Seres Therapeutics Inc’s (NASDAQ:MCRB) Investigational New Drug (IND) application for SER-155 to initiate Phase 1 trial.…
WeedMD Wraps Up Fiscal 2020 With $29.4M In Revenue, Reports Q1 2021 Preliminary Gross Revenue Of $12M
Medical cannabis company WeedMD Inc. (TSXV: WMD) (OTCQX: WDDMF) (FSE:4WE) reported Monday its revenue rose by 41% year-over-year, reaching CA$29.4 million ($24.3 million) in 2020.
BeyondSpring’s Plinabulin US Application for Chemo-Induced Neutropenia Under Review
The FDA has accepted for review BeyondSpring Inc’s (NASDAQ:BYSI) marketing application seeking approval for the use of plinabulin in combination with…